TLX: Telix Pharmaceuticals Ltd insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
62 institutions reported holding $36.16M of Telix Pharmaceuticals Ltd on Form 13F (40 the quarter before). 24 opened a new position and 1 sold out. Shares held by institutions: +22%.
| Largest holders | Shares | Value |
|---|---|---|
| FMR LLC | 561,206 | $6.47M |
| LAZARD ASSET MANAGEMENT LLC | 284,207 | $3.28M |
| PORTLAND INVESTMENT COUNSEL INC. | 266,200 | $3.07M |
| Private Advisor Group, LLC | 197,250 | $2.27M |
| MARSHALL WACE, LLP | 189,188 | $2.18M |
| MORGAN STANLEY | 165,978 | $1.91M |
| Integrated Wealth Concepts LLC | 164,397 | $1.90M |
| Hennion & Walsh Asset Management, Inc. | 150,138 | $1.73M |
| UBS Group AG | 134,698 | $1.55M |
| BLAIR WILLIAM & CO/IL | 122,985 | $1.42M |
Clinical trial readouts
3 Phase 2 or 3 trials by Telix Pharmaceuticals Ltd with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-01 (est.) | 68Ga-PSMA-11 | PCA | Phase 3 | 338 | Enrollment complete | NCT07052214 |
| 2027-07 (est.) | TLX-101-Tx + Lomustine | Neoplastic Disease | Phase 3 | 50 | Recruiting | NCT07100730 |
| 2027-08-31 (est.) | 177Lu-TLX250 | ccRCC | Phase 3 | 40 | Recruiting | NCT07197580 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.